Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Fineline Cube Apr 28, 2026
Company Drug

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

Fineline Cube Apr 28, 2026
Company Drug

Shanghai Henlius Biotech’s HanSiZhuang Shows Positive Results in Phase III ASTRUM-002 Study

Fineline Cube Nov 1, 2023

Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company in China, has unveiled positive...

Company Drug

Luye Pharma Group’s Rivastigmine Patch LY03013 Approved by China’s NMPA for Alzheimer’s Treatment

Fineline Cube Nov 1, 2023

China-based Luye Pharma Group (HKG: 2186) has announced that it has received market approval from...

Company

Bio-Techne Corporation Reports 2% YOY Revenue Growth in Q1 2024 Fiscal Report

Fineline Cube Nov 1, 2023

US-based life sciences service provider Bio-Techne Corporation (NASDAQ: TECH) has released its Q1 report for...

Company Drug

Novartis’ Cosentyx Gains FDA Approval for Hidradenitis Suppurativa Treatment

Fineline Cube Nov 1, 2023

The US Food and Drug Administration (FDA) has issued regulatory approval for Novartis’ (NYSE: NVS)...

Company Deals

AnHeart Therapeutics Signs Exclusive License Deal with Nippon Kayaku for Taletrectinib

Fineline Cube Nov 1, 2023

China-based AnHeart Therapeutics has announced the signing of an exclusive license deal with Japan-based biopharma...

Company Drug

Roche’s Gene Therapy Elevidys Misses Primary Endpoint in DMD Trial

Fineline Cube Nov 1, 2023

Switzerland-headquartered pharmaceutical giant Roche (SWX: ROG) has announced that a Phase III trial for its...

Company Deals

BioLineRx Licenses Multiple Myeloma Drug Motixafortide to Guangzhou Gloria Biosciences

Fineline Cube Nov 1, 2023

Israel’s BioLineRx has entered into a licensing agreement with Guangzhou Gloria Biosciences Co., Ltd., based...

Drug

Amgen Reports Q3 2023 Financials: 5% Growth Driven by Volume Expansion

Fineline Cube Nov 1, 2023

Amgen (NASDAQ: AMGN) has released its Q3 2023 financial results, showcasing a 5% year-on-year (YOY)...

Policy / Regulatory

Guangxi HSA Expands Coverage for Assisted Reproductive Medical Services Under BMI

Fineline Cube Nov 1, 2023

The Healthcare Security Administration (HSA) bureau of the Guangxi Zhuang Autonomous Region has announced a...

Company Medical Device

Siyi Intelligence Secures Approval for Innovative Rehabilitation Robots in China

Fineline Cube Nov 1, 2023

Shanghai-based Siyi Intelligence, a developer of soft rehabilitation robots, has announced that it has received...

Company Deals

Triastek Partners with BASF to Advance 3D Printing Materials for Pharmaceuticals

Fineline Cube Nov 1, 2023

China-based Triastek Inc., a leader in pharmaceutical-focused 3D printing, has announced a strategic partnership with...

Company Deals

Novo Nordisk Acquires Global License for Vect-Horus Molecular Cargo Delivery Platform

Fineline Cube Oct 31, 2023

Novo Nordisk (NYSE: NVO), a leading pharmaceutical company based in Denmark, has obtained an exclusive...

Company Deals

Merck KGaA and Jiangsu Hengrui Ink Strategic Collaboration Deal for Next-Gen PARP1 Inhibitor

Fineline Cube Oct 31, 2023

Germany-based Merck KGaA (NYSE: MRK) has announced the signing of a strategic collaboration deal with...

Company Drug

Coherus’s Loqtorzi Gains FDA Approval for Nasopharyngeal Carcinoma Treatment

Fineline Cube Oct 31, 2023

Coherus Biosciences (NASDAQ: CHRS) executives held an investor conference call on October 30, 2023, to...

Company Drug

Staidson Receives NMPA Approval for Clinical Trial of STSA-1301 in Primary Immune Thrombocytopenia

Fineline Cube Oct 31, 2023

Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a China-based pharmaceutical company, has announced that it...

Company Drug

Allist Pharmaceuticals’ Furmonertinib Receives FDA Breakthrough Therapy Designation for NSCLC

Fineline Cube Oct 31, 2023

Shanghai-based biotech Allist Pharmaceuticals Co., Ltd (SHA: 688578) has announced that it has received breakthrough...

Company Drug

Yirui Pharmaceutical’s YR001 Completes Successful Phase I Clinical Study in the US

Fineline Cube Oct 31, 2023

Hangzhou-based Yirui Pharmaceutical Technology Co., Ltd has announced the successful conclusion of a Phase I...

Company Deals

Danyang Huichuang Secures Over USD 13.7 Million in Series B Funding for fNIRS Development

Fineline Cube Oct 31, 2023

Danyang Huichuang Medical Equipment Co., Ltd, a China-based specialist in functional near-infrared spectroscopy (fNIRS), has...

Company Drug

CDE Grants Priority Review to LaNova’s LM-302, Roche’s Alectinib, and Alphamab’s KN026

Fineline Cube Oct 31, 2023

China’s Center for Drug Evaluation (CDE) has indicated that LaNova Medicines’ LM-302, Roche’s (SWX: ROG)...

Company Drug

Boan Biotech Enrolls First Patient in Phase III Study for Opdivo Biosimilar BA1104 in China

Fineline Cube Oct 31, 2023

Boan Biotech (HKG: 6955), a biopharmaceutical company based in China, has announced the enrollment of...

Posts pagination

1 … 443 444 445 … 658

Recent updates

  • Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform
  • Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise
  • AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise
  • GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development
  • Prothena’s Coramitug Receives FDA Fast Track Designation for ATTR-CM – Advancing Novo Nordisk’s $1.2B Amyloidosis Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Company Drug

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

Company Drug

AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise

Company Drug

GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.